Networking the Leishmania research community for the development of novel anti-leishmanial intervention strategies
2011
Networking the Leishmania Research Community for New Treatments
publication
Author Information
Author(s): Späth Gerald F, Roberto Bruzzone
Primary Institution: Institut Pasteur
Hypothesis
The LEISHDRUG consortium aims to exploit Leishmania kinome for anti-parasitic drug development.
Conclusion
The consortium is developing innovative strategies to identify and optimize new anti-leishmanial compounds.
Supporting Evidence
- The LEISHDRUG consortium coordinates efforts across 13 partners in eight nations.
- The consortium employs both phenotype- and target-based strategies for drug development.
- Innovative screening methods are used to identify compounds that kill Leishmania without harming host cells.
Takeaway
A group of scientists is working together to find new medicines to fight a disease caused by tiny parasites called Leishmania.
Methodology
The study uses innovative drug screening concepts and in silico analysis to identify potential drug targets and compounds.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website